转移性肺大细胞神经内分泌癌临床病理异质性及临床试验指南建议
该回顾性研究纳入137例转移性肺大细胞神经内分泌癌患者,其中纯LCNEC 100例、混合组织学37例、转化性LCNEC 15例。基因数据可用的115例中,55%归类为NSCLC样、37%为SCLC样。一线治疗中位OS在原发性LCNEC为10.0个月、tLCNEC为16.3个月;NSCLC方案与SCLC方案、化疗联合免疫与单纯化疗之间OS均无统计学差异。作者据此提出针对该人群前瞻性试验的指南建议。
要点
- 转移性LCNEC预后差,原发LCNEC一线治疗中位OS仅10.0个月。
- 按NSCLC或SCLC方案治疗及加用免疫治疗均未见OS统计学差异。
- 部分接受寡转移局部治疗的tLCNEC患者获长期疾病控制。
核心结论
- 转移性LCNEC临床结局差,按分子分型应用标准治疗未见明确获益关联。
- 基于上述数据提出针对新型治疗前瞻性试验开发的指南建议。
研究设计与样本
- 大型回顾性系列研究,共纳入137例新诊断转移性LCNEC患者。
- 纳入纯LCNEC 100例、混合组织学37例,其中转化性LCNEC 15例。
- 疑似转化性LCNEC者经病理复核,结局采用Kaplan-Meier法评估。
主要发现
- 基因数据可用的115例中,63例(55%)为NSCLC样、43例(37%)为SCLC样。
- 一线治疗起中位OS:原发LCNEC 10.0个月(95%CI 8.6-11.9),tLCNEC 16.3个月(9.4-40)。
- NSCLC方案与SCLC方案中位OS分别为12.1个月(10.0-17.6)与9.4个月(6.3-11.2),无统计学差异。
- 化疗联合免疫与单纯化疗中位OS分别为9.9个月(7.7-13.9)与10.4个月(8.6-14.1),无统计学差异。
- 部分接受寡转移局部治疗的tLCNEC患者获长期疾病控制。
临床怎么用
- 现有分子分型指导的标准治疗未显示OS获益,不应据此常规选择NSCLC或SCLC方案。
- 对寡转移tLCNEC可考虑局部治疗以期长期疾病控制。
- 鼓励患者参加针对LCNEC新型治疗的前瞻性临床试验。
局限性
- 为回顾性系列研究,存在选择偏倚等固有局限。
- 部分患者缺乏基因组数据,分子分型分析仅基于115例。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
INTRODUCTION: Pulmonary large cell neuroendocrine carcinoma (LCNEC) is a high-grade neuroendocrine carcinoma with clinical and molecular heterogeneity distinct from SCLC. This large retrospective series seeks to define the clinical outcomes for patients with newly diagnosed metastatic LCNEC and whether aligning treatment based on molecular classification improves outcomes. METHODS: Clinicopathologic data included demographics, treatment history, and immunohistochemical and genomic results. Patients with suspected transformed LCNEC (tLCNEC) underwent curated pathology review. Patient outcomes were assessed using Kaplan-Meier methodology. RESULTS: A total of 137 patients were included (100 with pure LCNEC and 37 with mixed histologies), of whom 15 had tLCNEC. For the 115 cases with genomic data available, 63 (55%) were classified as NSCLC like and 43 (37%) as SCLC like. The median overall survival (OS) from the start of first-line therapy was 10.0 months (95% confidence interval: 8.6-11.9) for patients with primary LCNEC and 16.3 months (9.4-40) for tLCNEC. There was no statistical difference in OS between patients treated with NSCLC or SCLC regimens (median OS: 12.1 mo [10.0-17.6] versus 9.4 mo [6.3-11.2]) or with the addition of immunotherapy to chemotherapy (median OS: 9.9 mo [7.7-13.9] versus 10.4 mo [8.6-14.1]). Several patients with tLCNEC who received local therapies for oligometastatic disease had long-term disease control. CONCLUSIONS: Clinical outcomes for patients with LCNEC are poor, with no clear association of benefit observed through the application of molecularly classified standard treatments. Based on these data, we propose guidelines for the development of prospective trials of novel therapeutics aimed at addressing the unmet needs of this patient population.
引用
- Choudhury NJ, Gezelius E, Arfe A, et al. Brief Report: Proposed Clinical Trial Guidelines Based on Clinicopathologic Heterogeneity of Metastatic Pulmonary Large Cell Neuroendocrine Carcinoma. J Thorac Oncol. 2026. PMID: 42341877. doi:10.1016/j.jtho.2026.104061
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。